Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchardâ??s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Childrenâ??s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Orchard Therapeutics plc - ADR market cap is $379.55M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Orchard Therapeutics plc - ADR 52 week high is $16.72 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Orchard Therapeutics plc - ADR 52 week low is $4.24 as of November 22, 2026.
Orchard Therapeutics plc - ADR stock price today is $16.70.
Orchard Therapeutics plc - ADR stock price yesterday was $16.65.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Orchard Therapeutics plc - ADR's P/E ratio is -1.27.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Orchard Therapeutics plc - ADR P/B ratio is 9.4582.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company's operations. Orchard Therapeutics plc - ADR's EBITDA is -0.93.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Orchard Therapeutics plc - ADR 50-day moving average is $16.43.